Figure 3 | Scientific Reports

Figure 3

From: A novel protective role of sacubitril/valsartan in cyclophosphamide induced lung injury in rats: impact of miRNA-150-3p on NF-κB/MAPK signaling trajectories

Figure 3

The effect of pretreatment with ENT (30 mg/kg; p.o.) for 6 days, and VAL (15 mg/kg; p.o.) for 6 days, in CP-treated rats (200 mg/kg; i.p.) single dose on day 5, on p38 and ERK1/2 MAPKs, (A): the cropped pattern of the protein expression of p38 and ERK1/2 MAPKs, (B): the relative proteins expression. ENT (sacubitril/valsartan), CP (cyclophosphamide), VAL (valsartan). Data are expressed as mean ± SD (n = 6). Multiple comparisons were performed using one-way ANOVA followed by Tukey’s as post hoc test; *P < 0.05, versus the control group; #P < 0.05, versus the CP-treated group. The full-length blots are presented in the supplementary figure.

Back to article page